News Release

Printer Friendly Version View printer-friendly version
« Back
Insys Therapeutics Hires Four Key Pharmaceutical Industry Veterans for Leadership Positions

PHOENIX, June 20, 2017 (GLOBE NEWSWIRE) -- Insys Therapeutics, Inc. (NASDAQ:INSY) (“Insys” or “the Company”) today announced the addition of four pharmaceutical industry veterans to its management team. Joining Insys are:

  • Brian Jennings, Vice President of Sales
  • Dr. Dean Mariano, Senior Director, Clinical Development/Medical Affairs;
  • Ariyapadi (Krishna) Krishnaraj, Vice President of Marketing and Managed Care; and,
  • Scott Warlick, General Manager, Manufacturing

“These key hires both elevate and diversify the talent within this growing organization,” said Saeed Motahari, President and Chief Executive Officer of Insys.  “We are delighted to welcome Brian, Dean, Krishna and Scott to the Company. Each of these executives brings highly relevant experience to Insys, and we look forward to their contributions as we execute our mission of improving the quality of care for patients in need.”

Brian Jennings, Vice President of Sales, is a skilled executive with more than 25 years of experience in the pharmaceutical industry and has a proven track record of successfully developing, motivating and leading commercial teams.  Throughout his extensive career, Mr. Jennings has held increasingly senior roles at organizations including Publicis Healthcare Group, Sanofi, Roche U.S. (Genentech), Unimed, and Searle.  As Vice President of Sales at Sanofi, he built and successfully managed Sanofi’s first oncology sales force.  While at Genentech, Mr. Jennings served as the Director of Sales and drove growth for the oncology portfolio.  Prior to joining Insys, he served as the Regional Business Director of Sales at Purdue Pharma. 

Dr. Dean Mariano, Insys’ new Senior Director, Clinical Development/Medical Affairs, is a practicing physician focused on pain management treatments with clinical interest in addiction and cancer patient populations. He has lectured extensively across the country on the topic of safe opioid prescribing. He was previously Medical Director at The Spine and Pain Institute and Section Chief of Pain Medicine at MidState Medical Center in Connecticut. Dr. Mariano is a Diplomat of the American Board of Anesthesiology and holds a subspecialty certification in Pain Medicine.  His leadership positions include President of the Connecticut Pain Society, Chairman of the Connecticut State Medical Society’s Task Force on Opioids and serves as a Ct. State Police Surgeon. He is a member of the American Society of Anesthesiologists and is an Assistant Professor at Quinnipiac University, Frank H. Netter, M.D. School of Medicine.

Ariyapadi Krishnaraj joins Insys as Vice President of Marketing and Managed Care with over 30 years of pharmaceutical industry experience. As the Vice President of Marketing at Novartis, Mr. Krishnaraj led the marketing and market research efforts to launch innovative programs with pharmacies and develop global pricing policies for vaccines.  As an Executive Director at GlaxoSmithKline, he successfully launched multiple products and various patient-focused educational campaigns.  Throughout his career, he has successfully planned and built an analytically-driven, patient-focused marketing and managed markets teams.  He most recently served at Iroko and as a consultant for various pharmaceutical companies including Endo and Takeda.

Scott Warlick is a proven senior leader in the pharmaceutical and specialty chemicals industry with over 25 years of experience in pharmaceutical manufacturing plant experience across operations, maintenance, process optimization, quality, and safety.  He was most recently Senior Director of Manufacturing at Mylan Laboratories, prior to which Mr. Warlick was with Mallinckrodt Pharmaceuticals where he held increasingly senior positions across the manufacturing organization. 

About Insys Therapeutics

Insys Therapeutics is a specialty pharmaceutical company that develops and commercializes innovative drugs and novel drug delivery systems of therapeutic molecules that improve the quality of life of patients. Using proprietary sublingual spray technology and capabilities to develop pharmaceutical cannabinoids, Insys is developing a pipeline of products intending to address unmet medical needs and the clinical shortcomings of existing commercial products. Insys currently markets one product, SUBSYS® (fentanyl sublingual spray), CII, and has received approval for the marketing of SYNDROS™ (dronabinol) oral solution, CII, a proprietary, orally administered liquid formulation of dronabinol that Insys believes has distinct advantages over the current formulation of dronabinol in soft gel capsule. Insys is committed to developing medications for potentially treating addiction to opioids, opioid overdose, epilepsy, and other disease areas with a significant unmet need.

SUBSYS® and SYNDROS™ are trademarks of Insys Development Company, Inc., a subsidiary of Insys Therapeutics, Inc.

Forward-Looking Statements 

This press release contains forward-looking statements including regarding our belief that SYNDROS™ has distinct advantages over the current formulation of dronabinol in soft gel capsules.   These forward-looking statements are based on management's expectations and assumptions as of the date of this press release; actual results may differ materially from those in these forward-looking statements as a result of various factors, many of which are beyond our control. These factors include, but are not limited to risk factors described in our filings with the United States Securities and Exchange Commission, including those factors discussed under the caption "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2016 and subsequent updates that may occur in our Quarterly Reports on Form 10-Q. Forward-looking statements speak only as of the date of this press release and we undertake no obligation to publicly update or revise these statements, except as may be required by law.

NOTE: All trademarks and registered trademarks are the property of their respective owners.

Investor Contact:
Lisa M. Wilson
President
In-Site Communication, Inc.
212-452-2793

Primary Logo

Insys Therapeutics, Inc.